(SSYS) Stratasys - Overview
Sector: Technology | Industry: Computer Hardware | Exchange: NASDAQ (USA) | Market Cap: 741m USD | Total Return: -13.8% in 12m
Avg Turnover: 5.71M
Qual. Beats: 0
Rev. Trend: -96.8%
Qual. Beats: 0
Warnings
Share dilution 20.0% YoY
High Debt/EBITDA (6.5) with thin interest coverage (-3.9)
High Debt while negative Cash Flow
Interest Coverage Ratio -3.9 is critical
Altman Z'' -15.00 < 1.0 - financial distress zone
Choppy
Tailwinds
No distinct edge detected
Stratasys Ltd. (SSYS) specializes in polymer-based 3D printing solutions, utilizing technologies such as Fused Deposition Modeling (FDM), PolyJet, and Stereolithography (SLA). The company’s portfolio spans hardware, proprietary resins, and software designed for prototyping and end-use production across the medical, dental, and fashion industries. Its specialized medical segment features the Digital Anatomy Creator and bio-mechanical resins used to simulate human tissue and bone for device testing.
The 3D printing sector operates on a razor-and-blade business model, where the installation of hardware drives recurring high-margin revenue through the sale of proprietary consumables and service contracts. As industrial additive manufacturing shifts from rapid prototyping to functional part production, companies like Stratasys focus on material science and software integration to improve print precision and speed. Investors looking for a deeper dive into these fundamentals may find ValueRays analytical tools useful for further due diligence.
Headquartered in Minnesota, the firm integrates its GrabCAD software platform with various printer lines, including the Origin P3 and SAF systems, to streamline manufacturing workflows. This ecosystem supports high-fidelity color printing and direct-to-textile applications, positioning the company within the broader technology hardware and peripherals landscape.
- Expansion of industrial manufacturing adoption for end-use production parts
- Growth in medical and dental resin sales drives recurring revenue margins
- Macroeconomic capital expenditure constraints limit high-end hardware system placements
- Consolidation activity and takeover bids influence short-term share price volatility
- Innovation in multi-material fashion and anatomical printing opens new vertical markets
| Net Income: -115.1m TTM > 0 and > 6% of Revenue |
| FCF/TA: -0.01 > 0.02 and ΔFCF/TA -0.04 > 1.0 |
| NWC/Revenue: 71.74% < 20% (prev 60.16%; Δ 11.58% < -1%) |
| CFO/TA 0.01 > 3% & CFO 13.0m > Net Income -115.1m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 3.17 > 1.5 & < 3 |
| Outstanding Shares: last quarter (86.4m) vs 12m ago 20.00% < -2% |
| Gross Margin: 43.12% > 18% (prev 0.44%; Δ 4.27k% > 0.5%) |
| Asset Turnover: 52.27% > 50% (prev 55.17%; Δ -2.90% > 0%) |
| Interest Coverage Ratio: -3.88 > 6 (EBITDA TTM -32.4m / Interest Expense TTM 19.6m) |
| A: 0.37 (Total Current Assets 573.6m - Total Current Liabilities 180.7m) / Total Assets 1.07b |
| B: -2.28 (Retained Earnings -2.45b / Total Assets 1.07b) |
| C: -0.07 (EBIT TTM -76.2m / Avg Total Assets 1.05b) |
| D: -9.92 (Book Value of Equity -2.45b / Total Liabilities 247.3m) |
| Altman-Z'' = -15.94 = D |
| DSRI: 1.04 (Receivables 157.1m/156.2m, Revenue 547.8m/564.5m) |
| GMI: 1.02 (GM 43.12% / 44.15%) |
| AQI: 0.90 (AQ_t 0.26 / AQ_t-1 0.29) |
| SGI: 0.97 (Revenue 547.8m / 564.5m) |
| TATA: -0.12 (NI -115.1m - CFO 13.0m) / TA 1.07b) |
| Beneish M = -3.18 (Cap -4..+1) = AA |
As of May 24, 2026, the stock is trading at USD 8.53 with a total of 497,994 shares traded.
Over the past week, the price has changed by +5.37%,
over one month by +3.20%,
over three months by -10.96% and
over the past year by -13.77%.
Stratasys has received a consensus analysts rating of 4.25. Therefore, it is recommended to buy SSYS.
- StrongBuy: 2
- Buy: 1
- Hold: 1
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 12.3 | 44.5% |
P/S = 1.3519
P/B = 0.898
P/EG = 2.0632
Revenue TTM = 547.8m USD
EBIT TTM = -76.2m USD
EBITDA TTM = -32.4m USD
Long Term Debt = 19.5m USD (estimated: total debt 26.7m - short term 7.14m)
Short Term Debt = 7.14m USD (from shortTermDebt, last quarter)
Debt = 26.7m USD (from shortLongTermDebtTotal, last quarter) (leases 26.7m already included)
Net Debt = -211.1m USD (calculated: Debt 26.7m - CCE 237.8m)
Enterprise Value = 529.4m USD (740.5m + Debt 26.7m - CCE 237.8m)
Interest Coverage Ratio = -3.88 (Ebit TTM -76.2m / Interest Expense TTM 19.6m)
EV/FCF = -54.31x (Enterprise Value 529.4m / FCF TTM -9.75m)
FCF Yield = -1.84% (FCF TTM -9.75m / Enterprise Value 529.4m)
FCF Margin = -1.78% (FCF TTM -9.75m / Revenue TTM 547.8m)
Net Margin = -21.01% (Net Income TTM -115.1m / Revenue TTM 547.8m)
Gross Margin = 43.12% ((Revenue TTM 547.8m - Cost of Revenue TTM 311.6m) / Revenue TTM)
Gross Margin QoQ = 42.39% (prev 45.98%)
Tobins Q-Ratio = 0.49 (Enterprise Value 529.4m / Total Assets 1.07b)
Interest Expense / Debt = 73.64% (Interest Expense 19.6m / Debt 26.7m)
Taxrate = 21.0% (US default 21%)
NOPAT = -60.2m (EBIT -76.2m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 3.17 (Total Current Assets 573.6m / Total Current Liabilities 180.7m)
Debt / Equity = 0.03 (Debt 26.7m / totalStockholderEquity, last quarter 825.6m)
Debt / EBITDA = 6.51 (negative EBITDA) (Net Debt -211.1m / EBITDA -32.4m)
Debt / FCF = 21.66 (negative FCF - burning cash) (Net Debt -211.1m / FCF TTM -9.75m)
Total Stockholder Equity = 855.9m (last 4 quarters mean from totalStockholderEquity)
RoA = -10.98% (Net Income -115.1m / Total Assets 1.07b)
RoE = -3.48% (Net Income TTM -115.1m / Total Stockholder Equity 3.30b)
RoCE = -2.29% (EBIT -76.2m / Capital Employed (Equity 3.30b + L.T.Debt 19.5m))
RoIC = -7.07% (negative operating profit) (NOPAT -60.2m / Invested Capital 852.0m)
WACC = 11.83% (E(740.5m)/V(767.2m) * Re(12.26%) + (debt cost/tax rate unavailable))
Discount Rate = 12.26% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 100.00 | Cagr: 10.22%
[DCF] Fair Price = unknown (Cash Flow -9.75m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -0.27 | # QB: 0
Revenue Correlation: -96.78 | Revenue CAGR: -5.74% | SUE: 0.27 | # QB: 0
EPS current Quarter (2026-06-30): EPS=0.01 | Chg30d=N/A | Revisions=-20% | Analysts=4
EPS next Quarter (2026-09-30): EPS=0.04 | Chg30d=N/A | Revisions=+0% | Analysts=4
EPS current Year (2026-12-31): EPS=0.12 | Chg30d=+2.13% | Revisions=+20% | GrowthEPS=-20.0% | GrowthRev=+3.0%
EPS next Year (2027-12-31): EPS=0.18 | Chg30d=+5.88% | Revisions=+0% | GrowthEPS=+50.0% | GrowthRev=+3.7%
[Analyst] Revisions Ratio: -20%